| Code | CSB-RA723415MB14HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Uliledlimab, targeting NT5E (5'-nucleotidase ecto, also known as CD73). NT5E is an ectoenzyme that catalyzes the conversion of extracellular adenosine monophosphate to adenosine, playing a critical role in purinergic signaling and immune regulation. By generating adenosine in the tumor microenvironment, NT5E promotes immunosuppression through adenosine receptor activation, which inhibits T cell and NK cell function while promoting regulatory T cell activity. Elevated NT5E expression is associated with multiple cancers, including triple-negative breast cancer, melanoma, and ovarian cancer, where it contributes to immune evasion and poor prognosis.
Uliledlimab is a clinical-stage therapeutic antibody designed to block NT5E enzymatic activity, thereby reducing adenosine production and relieving immunosuppression in the tumor microenvironment. This biosimilar antibody serves as a valuable research tool for investigating adenosine-mediated immune regulation, exploring combination immunotherapy strategies, and studying NT5E biology in cancer and inflammatory disease models.
There are currently no reviews for this product.